<DOC>
	<DOC>NCT01004614</DOC>
	<brief_summary>This study is being conducted to determine if 5 mg amlodipine 3rd Orally-Disintegrating (OD) tablet (new formulation) and 5 mg amlodipine 2nd OD tablet (commercial formulation) are bioequivalent.</brief_summary>
	<brief_title>Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy; Body Mass Index (BMI) of 18 to 28 kg/m2; total body weight within the range of 50 to 100 kg History of regular alcohol consumption exceeding 14 drinks/week Use of tobacco or nicotinecontaining products in excess of the equivalent of 10 cigarettes per day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>